Cocrystal Pharma Inc

Research Cocrystal Pharma Inc (COCP) on Bullrun: market cap USD 15.58M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 15.58M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 8.83M-USD 8.20Mn/a-0.78USD 7.03MUSD 1.51MUSD 6.33M
FY2024USD 0-USD 17.50M-USD 16.49Mn/a-1.72USD 9.86MUSD 1.81MUSD 9.52M
FY2023n/a-USD 17.98M-USD 14.78Mn/a-1.87USD 26.35MUSD 1.85MUSD 26.38M
FY2022n/a-USD 38.84M-USD 21.51Mn/a-4.77USD 37.14MUSD 419.00KUSD 39.60M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 15.58Mn/an/an/a
20252025-12-31USD 13.51Mn/an/an/a
20242024-12-31USD 20.55Mn/an/an/a
20232023-12-29USD 17.50Mn/an/an/a
20222022-12-30USD 15.88Mn/an/an/a
20212021-12-31USD 63.35Mn/an/an/a

About Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Cocrystal Pharma Inc's market cap?

Cocrystal Pharma Inc's market capitalization is USD 15.58M.

What does Cocrystal Pharma Inc do?

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.